William Aliski - Net Worth and Insider Trading

William Aliski Net Worth

The estimated net worth of William Aliski is at least $4 Million dollars as of 2024-11-13. William Aliski is the Director of Ultragenyx Pharmaceutical Inc and owns about 75,160 shares of Ultragenyx Pharmaceutical Inc (RARE) stock worth over $4 Million. William Aliski is also the Director of Applied Genetic Technologies Corp and owns about 8,500 shares of Applied Genetic Technologies Corp (AGTC) stock worth over $3,346. Details can be seen in William Aliski's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that William Aliski has not made any transactions after 2021-02-19 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of William Aliski

To

William Aliski Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, William Aliski owns 3 companies in total, including Ultragenyx Pharmaceutical Inc (RARE) , X4 Pharmaceuticals Inc (XFOR) , and Applied Genetic Technologies Corp (AGTC) .

Click here to see the complete history of William Aliski’s form 4 insider trades.

Insider Ownership Summary of William Aliski

Ticker Comapny Transaction Date Type of Owner
RARE Ultragenyx Pharmaceutical Inc 2021-02-19 director
XFOR X4 Pharmaceuticals Inc 2019-09-18 director
AGTC Applied Genetic Technologies Corp 2021-11-30 director

William Aliski Latest Holdings Summary

William Aliski currently owns a total of 2 stocks. Among these stocks, William Aliski owns 75,160 shares of Ultragenyx Pharmaceutical Inc (RARE) as of February 19, 2021, with a value of $4 Million and a weighting of 99.91%. William Aliski also owns 8,500 shares of Applied Genetic Technologies Corp (AGTC) as of December 14, 2018, with a value of $3,346 and a weighting of 0.09%.

Latest Holdings of William Aliski

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
RARE Ultragenyx Pharmaceutical Inc 2021-02-19 75,160 48.75 3,664,050
AGTC Applied Genetic Technologies Corp 2018-12-14 8,500 0.39 3,346

Holding Weightings of William Aliski


William Aliski Form 4 Trading Tracker

According to the SEC Form 4 filings, William Aliski has made a total of 4 transactions in Ultragenyx Pharmaceutical Inc (RARE) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in Ultragenyx Pharmaceutical Inc is the sale of 7,500 shares on February 19, 2021, which brought William Aliski around $1 Million.

According to the SEC Form 4 filings, William Aliski has made a total of 0 transactions in Applied Genetic Technologies Corp (AGTC) over the past 5 years. The most-recent trade in Applied Genetic Technologies Corp is the acquisition of 6,000 shares on December 14, 2018, which cost William Aliski around $19,500.

Insider Trading History of William Aliski

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

William Aliski Trading Performance

GuruFocus tracks the stock performance after each of William Aliski's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by William Aliski is 33.23%. GuruFocus also compares William Aliski's trading performance to market benchmark return within the same time period. The performance of stocks bought by William Aliski within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how William Aliski's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of William Aliski

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -4.31 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -3.64 LIMIT LIMIT LIMIT LIMIT LIMIT

William Aliski Ownership Network

Ownership Network List of William Aliski

No Data

Ownership Network Relation of William Aliski

Insider Network Chart

William Aliski Owned Company Details

What does Ultragenyx Pharmaceutical Inc do?

Who are the key executives at Ultragenyx Pharmaceutical Inc?

William Aliski is the director of Ultragenyx Pharmaceutical Inc. Other key executives at Ultragenyx Pharmaceutical Inc include Chief Financial Officer Howard Horn , director & 10 percent owner & President & CEO Emil D Kakkis , and Controller and PAO Theodore Alan Huizenga .

Ultragenyx Pharmaceutical Inc (RARE) Insider Trades Summary

Over the past 18 months, William Aliski made no insider transaction in Ultragenyx Pharmaceutical Inc (RARE). Other recent insider transactions involving Ultragenyx Pharmaceutical Inc (RARE) include a net sale of 147,853 shares made by Emil D Kakkis , a net sale of 4,391 shares made by Sanders Corazon (corsee) D. , and a net sale of 3,565 shares made by Theodore Alan Huizenga .

In summary, during the past 3 months, insiders sold 27,556 shares of Ultragenyx Pharmaceutical Inc (RARE) in total and bought 0 shares, with a net sale of 27,556 shares. During the past 18 months, 260,421 shares of Ultragenyx Pharmaceutical Inc (RARE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 260,421 shares.

Ultragenyx Pharmaceutical Inc (RARE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Ultragenyx Pharmaceutical Inc Insider Transactions

No Available Data

William Aliski Mailing Address

Above is the net worth, insider trading, and ownership report for William Aliski. You might contact William Aliski via mailing address: C/o Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato Ca 94949.